Chemours reported Q4 2025 net sales of USD 1.33 billion (-2% YoY) and a net loss attributable to shareholders of USD 47 million, or USD 0.31 per diluted share, versus a net loss of USD 11 million a year earlier. Q4 adjusted net income was USD 7 million (USD 0.05 per diluted share) and adjusted EBITDA was USD 128 million (-24% YoY). Free cash flow in Q4 was USD 92 million, with free cash flow conversion of 72%. For FY 2025, Chemours posted net sales of USD 5.81 billion (flat YoY) and a net loss attributable to shareholders of USD 386 million, or USD 2.57 per diluted share, versus net income of USD 69 million in FY 2024. FY adjusted net income was USD 143 million (USD 0.95 per diluted share) and adjusted EBITDA was USD 742 million (-3% YoY). As of Dec. 31, 2025, gross debt was USD 4.20 billion and unrestricted cash and cash equivalents were USD 670 million, resulting in net debt of USD 3.50 billion and a net leverage ratio of about 4.7x. In Thermal & Specialized Solutions, Q4 net sales were USD 444 million (+14% YoY), including Opteon refrigerants net sales of USD 243 million (+37% YoY), with segment adjusted EBITDA of USD 128 million (+5% YoY). Titanium Technologies Q4 net sales were USD 561 million (-11% YoY) and segment adjusted EBITDA was USD 23 million (-67% YoY). Advanced Performance Materials Q4 net sales were USD 312 million (-4% YoY) and segment adjusted EBITDA was USD 12 million (-74% YoY), with Chemours citing a non-cash inventory charge of about USD 17 million and about USD 10 million tied to less favorable product mix to reduce inventory and promote cash flow. Chemours said it implemented a global TiO2 price increase effective Dec. 1, 2025, and announced the sale of its former Kuan Yin TiO2 site for about USD 300 million in net proceeds. CEO Denise Dignam said the quarter was highlighted by continued transition to Opteon refrigerants, while APM faced short-term cyclical headwinds and incurred a sizable non-cash inventory charge; she added that TiO2 pricing actions have begun to take effect and that the Kuan Yin site sale and higher organic cash flow generation are expected to provide significant cash inflow in 2026. For FY 2026, Chemours guided for net sales growth of 3% to 5% and adjusted EBITDA of USD 800 million to USD 900 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Chemours Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602191638PR_NEWS_USPR_____PH91900) on February 19, 2026, and is solely responsible for the information contained therein.